Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX...
Redeye comments on Beyond Frames Q2 2023 report, where net sales and profitability came in above est...
Will scale down VHP (tobacco) business by ~50% We expect initial revisions to be conservative (c.
Redeye thinks the Q2 report from Zwipe was significantly weaker than our estimates with zero revenue...
Redeye provides an initial take on SenzaGen’s H1 2023 report.
Redeye views favorably the news that Waystream has added Transtema as a partner in the Swedish marke...
Redeye believes Q2 was quite eventful for InDex Pharmaceuticals, with the highlight being a USD50m d...
Redeye provides a brief comment on Sprint Bioscience’s Q2 report.
Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum.
Redeye raises its base case following a case review of OssDsign and we positively reconsider its com...
Weak sales in both segments but better gross margin.
Vow's H1 results showed encouraging performance in both the Maritime and Aftersales divisions; howev...
Redeye updates its view on Artificial Solutions on the back its Q2 2023 report, where ARR and recurr...
Earnings forecast lowered by 5-25% Q2'23e sales increase of 7% Focus on the ongoing stategic process...
Zoomability publicerade den 23 augusti 2023 bolagets delårsrapport för årets andra kvartal.
Redeye comments on AVTECHs announcement where it upsold Aventus Wind Services to Volotea.
Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e...
